journal
MENU ▼
Read by QxMD icon Read
search

Drug and Therapeutics Bulletin

journal
https://www.readbyqxmd.com/read/29880701/there-is-no-news
#1
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
June 7, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875174/nhs-england-s-do-not-prescribe-list
#2
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875173/guidance-on-management-of-otitis-media-in-children
#3
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875172/risk-of-burns-with-flammable-treatments-for-head-lice
#4
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875171/safety-alert-change-of-colour-for-fast-acting-insulin-%C3%A2-fiasp-products
#5
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875170/antenatal-fetal-rhesus-d-testing
#6
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875169/cardiovascular-safety-of-febuxostat-and-allopurinol
#7
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29875168/lack-of-evidence-on-drugs-to-support-benzodiazepine-withdrawal
#8
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29903753/what-dose-of-paracetamol-for-older-people
#9
(no author information available yet)
Paracetamol, on its own or in combination with other analgesics, is widely used to treat pain associated with acute and chronic conditions. It is considered safe enough to have a general sales licence (GSL) for use by "adults, elderly and children over 16 years" and has few listed cautions or contraindications.1,2 However, recently the effectiveness and safety of paracetamol for some conditions have been challenged, 3,4 and there are published case reports of liver failure associated with therapeutic doses...
June 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29903752/what-place-is-there-for-tramadol-dexketoprofen
#10
(no author information available yet)
No single analgesic provides effective pain relief in all patients and increasing the dose of an analgesic may increase its unwanted effects.1 In addition, pain frequently results from multiple mechanisms that may respond to different pharmacological interventions.2 One suggested approach is to combine analgesics with different modes of action, with the aim of delivering better analgesia using lower doses of each drug.1 Skudexa (A. Menarini Farmaceutica Internazionale SRL), a combination of tramadol hydrochloride (a synthetic opioid analgesic that is a partial agonist at the μ, δ and κ opioid receptors) and dexketoprofen (a NSAID), is licensed for short term treatment of moderate to severe acute pain in adults...
June 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29760164/%C3%A2-bezlotoxumab-for-prevention-of-recurrence-of-clostridium-difficile-infection
#11
(no author information available yet)
Clostridium difficile infection is a significant cause of infectious diarrhoea and is associated with considerable morbidity and mortality.1,2 Management of Clostridium difficile infection often requires treatment with antibiotics (metronidazole, vancomycin or fidaxomicin) alongside supportive care to manage hydration, electrolytes and nutrition. However, the risk of recurrence is approximately 20%.2 Here, we review the evidence for bezlotoxumab (▼ Zinplava - Merck Sharp & Dohme Limited), a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile in adults who are at high risk of recurrence...
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29760163/%C3%A2-safinamide-for-parkinson-s-disease
#12
(no author information available yet)
▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson's disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson's disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29724772/does-pulmonary-rehabilitation-need-more-pr
#13
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703809/association-of-aortic-aneurysm-with-fluoroquinolones
#14
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703808/esmya-ulipristal-acetate-safety-update
#15
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703807/self-monitoring-and-telemonitoring-titration-of-antihypertensive-treatment
#16
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703806/strategies-for-reducing-medication-related-harm
#17
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703805/value-of-brief-alcohol-interventions-in-primary-care
#18
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703804/opioids-versus-non-opioids-for-chronic-musculoskeletal-pain
#19
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29703803/antidepressants-modest-effect-after-8-weeks
#20
(no author information available yet)
No abstract text is available yet for this article.
May 2018: Drug and Therapeutics Bulletin
journal
journal
21685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"